The first domestically developed combination therapy of neutralizing antibodies for COVID-19 has been approved by the National Medical Products Administration.


Release date:

2021-12-08

On December 8, the National Medical Products Administration granted emergency approval for the registration applications of BRII-196, a neutralizing antibody combination therapy against COVID‑19 developed by Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd., and BRII-198. This marks the first domestically developed, independently patented neutralizing antibody combination therapy for COVID‑19 to receive regulatory approval in China.

On December 8, the National Medical Products Administration granted emergency approval for the registration applications of BRII-196, an anti‑SARS‑CoV‑2 neutralizing antibody injection, and BRII-198, a neutralizing antibody injection, developed by Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. This marks the first domestically approved combination therapy based on neutralizing antibodies against SARS‑CoV‑2 that is protected by China’s own intellectual property rights.

According to reports, in accordance with relevant provisions of the Drug Administration Law and following the special drug approval procedure, the National Medical Products Administration has conducted an emergency review and approval, granting authorization for the combined use of the two aforementioned drugs to treat adult and adolescent patients (aged 12–17 years, weighing ≥40 kg) with mild or moderate COVID‑19 who have risk factors that may progress to severe disease, including hospitalization or death. Notably, the indication for adolescents (aged 12–17 years, weighing ≥40 kg) is granted under conditional approval.


Leave a Message Online

Please fill out the form, and we will get back to you as soon as possible!

Consultation Service Hotline

86-0717-6555905

Address: No. 509, East Lin Road, Bio-Industrial Park, High-tech Zone, Yichang City, Hubei Province, China

International Marketing Department

Contact: Vivian Guo

Email: Vivian.guo@tianrenpharm.com

Phone: 86-15997560212

WhatsApp: +86-15997560212


All rights reserved: Yichang Tianren Pharmaceutical Co., Ltd.

This website supports both IPv4 and IPv6 bidirectional access.

%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86%EF%BC%8C%E7%9F%A5%E5%90%8D%EF%BC%8C%E7%BA%A7

Sorry,当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry,The current column has no content!

You can view other columns or return Home